Pricing Log in Create free account
Friday 6 November 2026 Export ONC’s income statement to Excel — free account

BeOne Medicines Ltd. - Sponsored ADR

ONC Healthcare Biotechnology

BeOne Medicines Ltd. - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $5.3 billion, up 40.2% from fiscal 2024.

Revenue
+33.8%
EPS
+143.7%
Free cash flow
+33.6%
Total debt
+491.3%

Quarter to September 2026, against a year earlier

406.26 19.01 +4.91%
Market cap
$40.4B
P/E
65.9×
Fwd P/E
48.8×
Dividend yield
—
F-score
7/9
Altman Z
5.25
Beneish M
−2.73
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

BeOne Medicines Ltd. - Sponsored ADR 10-K filed Feb 26, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 6:09 AM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1, Business, against the 10-K filed Feb 27, 2025: 98 added · 58 removed · 170 modified; 15 with only figures updated; 4 moved without change

  1. Modified · Overview

    We are a leading global oncology company discovering and developing innovative treatments that are more accessible and affordable to cancer patients worldwide. In 20242025, we generated total global revenue of approximately $3.85.3 billion, increasing revenue by approximately $1.4 billion 40.2% from the prior year, while reducing our operating loss from the prior year achieving net income of $286.9 million, net cash provided by approximately operating activities of $0.61.1 billion and positive free cash flow of $941.7 million.

325 more changes in this Item, word by word, in Powerpack.